The preclinical treatment regimen evaluated in this study. The radioactive biopolymer (131I-ELP, where ELP stands for elastin-like polypeptide) is injected into the pancreatic tumor, and the radiosensitizing chemotherapeutic drug paclitaxel is delivered systemically.